PDS Biotechnology (NASDAQ: PDSB) reported Q1 EPS of ($0.14), $0.05 better than the analyst estimate of ($0.19).

“We look forward to the presentation of preliminary efficacy and safety data from the National Cancer Institute (NCI)-led Phase 2 combination study of PDS0101 at the ASCO conference in early June. ASCO provides an important opportunity to present the potential of PDS0101 and the Versamune® platform in oncology to the research and medical community,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech, “The presentation of the human clinical efficacy data at ASCO is an important milestone both for PDS0101 and our entire Versamune®-based oncology pipeline.”

For earnings history and earnings-related data on PDS Biotechnology (PDSB) click here.